Published in Br J Cancer on April 10, 2006
Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Womens Health (2010) 0.94
Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation. Breast Cancer Res (2007) 0.93
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer (2007) 0.90
Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy controls. BMC Cancer (2008) 0.86
Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes Control (2012) 0.81
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet (1999) 8.17
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science (1999) 2.54
The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology (1995) 2.27
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene (2001) 1.82
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81
Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene (2000) 1.59
Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci (2001) 1.57
BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol (2004) 1.43
Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol (2000) 1.35
New complexities for BRCA1 and BRCA2. Curr Biol (2001) 1.30
The pathology of familial breast cancer: Morphological aspects. Breast Cancer Res (1999) 1.11
BRCA1-associated tumorigenesis: what have we learned from knockout mice? Trends Genet (2001) 1.11
Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk. Environ Mol Mutagen (2002) 1.11
Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol (2001) 1.08
Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res Treat (1997) 1.07
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer (2004) 1.05
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. Clin Cancer Res (2004) 1.03
Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice. Transgenic Res (2002) 1.00
Genetic epidemiology of female breast cancer. Semin Cancer Biol (2001) 0.98
Expression of BRCA1 and BRCA2 in normal and neoplastic cells. J Mammary Gland Biol Neoplasia (1998) 0.97
Knockout mouse models and mammary tumorigenesis. Semin Cancer Biol (2001) 0.93
Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature (1986) 7.10
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Checking anaesthetic equipment 2012: association of anaesthetists of Great Britain and Ireland. Anaesthesia (2012) 5.41
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
The role of attention in the programming of saccades. Vision Res (1995) 3.92
Bougie-related airway trauma: dangers of the hold-up sign. Anaesthesia (2014) 3.53
Segmental Interchange in Chromosomes of Tradescantia. Genetics (1933) 3.49
Risks of acute traumatic intracranial haematoma in children and adults: implications for managing head injuries. BMJ (1990) 3.19
An in vitro method for assessing the plaque forming ability of oral bacteria. Arch Oral Biol (1967) 3.11
General practitioners and alternative medicine. J R Coll Gen Pract (1987) 3.10
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet (2004) 3.10
A study of diabetic patients at home. Am J Public Health Nations Health (1967) 2.95
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer (1984) 2.89
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet (2006) 2.68
Familial breast cancer. BMJ (1994) 2.54
Uptake of screening and prevention in women at very high risk of breast cancer. Lancet (2001) 2.45
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol (1997) 2.39
Perception of risk in women with a family history of breast cancer. Br J Cancer (1993) 2.32
Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol (1999) 2.32
The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology (1995) 2.27
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet (2003) 2.24
Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr (1998) 2.21
The effect of desiccated thryroid, irradiated ergosterol and ammonium chloride on the excretion of calcium in rats. Biochem J (1934) 2.05
Violent injuries among women in an urban area. N Engl J Med (1999) 2.04
Head injuries in accident and emergency departments. How different are children from adults? J Epidemiol Community Health (1990) 2.01
Haemophilus influenzae type b disease in the Oxford region. Arch Dis Child (1989) 1.95
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat (2001) 1.88
Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet (2008) 1.87
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat (1999) 1.84
Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer (1991) 1.83
Oocyte differentiation in the sea urchin, Arbacia punctulata, with particular reference to the origin of cortical granules and their participation in the cortical reaction. J Cell Biol (1968) 1.81
Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. Br J Cancer (2007) 1.80
Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab (1997) 1.79
Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. BMJ (1996) 1.79
Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet (2007) 1.77
The appearance and structure of intercellular connections during the ontogeny of the rabbit ovarian follicle with particular reference to gap junctions. J Cell Biol (1974) 1.77
Identification and localization of bacterial endosymbionts in hydrothermal vent taxa with symbiont-specific polymerase chain reaction amplification and in situ hybridization techniques. Mol Mar Biol Biotechnol (1993) 1.76
The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer (1994) 1.75
Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med (2000) 1.74
The fine structure of pronuclear development and fusion in the sea urchin, Arbacia punctulata. J Cell Biol (1968) 1.71
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 1.70
The preimplantation mammalian embryo: characterization of intercellular junctions and their appearance during development. Dev Biol (1975) 1.69
Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet (1983) 1.69
Interferometer-controlled scanning transmission X-ray microscopes at the Advanced Light Source. J Synchrotron Radiat (2003) 1.68
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer (1996) 1.67
The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer (1989) 1.65
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) (2010) 1.61
The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer (1984) 1.61
Odontomyces viscosus, gen. nov., spec. nov., a filamentous microorganism isolated from periodontal plaque in hamsters. Sabouraudia (1965) 1.61
Platelet-derived growth factor receptor alpha-subunit gene (Pdgfra) is deleted in the mouse patch (Ph) mutation. Proc Natl Acad Sci U S A (1991) 1.61
Prospective randomized controlled trial of preservation of the intercostobrachial nerve during axillary node clearance for breast cancer. Br J Surg (1998) 1.59
Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J Natl Cancer Inst (1997) 1.58
Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. J Urol (2007) 1.57
Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet (1984) 1.56
Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab (1996) 1.54
Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology (2002) 1.53
Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia (1998) 1.52
A filamentous microorganism isolated from periodontal plaque in hamsters. 1. Isolation, morphology and general cultural characteristics. Sabouraudia (1963) 1.52
Termination of paroxysmal supraventricular tachycardia by digital rectal massage. Ann Emerg Med (1987) 1.51
Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol (1996) 1.49
Cell shape and membrane changes in the eight-cell mouse embryo: prerequisites for morphogenesis of the blastocyst. Dev Biol (1975) 1.49
Can hair be used to screen for breast cancer? J Med Genet (2000) 1.49
Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem (2000) 1.48
Can preoperative factors predict for residual malignancy after breast biopsy for invasive cancer? Ann R Coll Surg Engl (1995) 1.47
Hemarthrosis and synovitis associated with hemophilia: clinical use of P-32 chromic phosphate synoviorthesis for treatment. Radiology (1994) 1.47
A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther (2000) 1.45
Neuropathic joints. Semin Arthritis Rheum (1972) 1.44
Screening by mammography, women with a family history of breast cancer. Eur J Cancer (1998) 1.44
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol (1996) 1.44
Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab (1999) 1.44
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am (2006) 1.43
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer (2004) 1.43
Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations. Clin Endocrinol (Oxf) (1994) 1.42
Gap junctions between the oocyte and companion follicle cells in the mammalian ovary. J Cell Biol (1976) 1.42
Active transport by the cecropia midgut. II. Fine structure of the midgut epithelium. J Cell Biol (1966) 1.42
Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab (1999) 1.42
The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. Br J Cancer (1988) 1.42
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer (2012) 1.39
Effect of clothing on dispersal of Staphylococcus aureus by males and females. Lancet (1974) 1.39
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole. Eur J Cancer (2004) 1.39
Microtubule and microfilament rearrangements during capping of concanavalin A receptors on cultured ovarian granulosa cells. J Cell Biol (1977) 1.38